- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
1859
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
1,859 companies
Chosa Oncology
Market Cap: SEK 34.4m
Develops oncology drugs for the treatment of cancer.
CHOSA
SEK 0.53
7D
0%
1Y
-59.2%
HyEnergy
Market Cap: zł94.0m
Provides genetic diagnostic solutions in Poland.
HEN
zł2.80
7D
0%
1Y
64.7%
GlaxoSmithKlineE
Market Cap: ج.م3.2b
Engages in production of pharmaceutical chemicals.
BIOC
ج.م37.80
7D
-0.4%
1Y
30.3%
Vaxil Bio
Market Cap: CA$1.4m
A biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.
VXL
CA$0.20
7D
n/a
1Y
-59.0%
Propanc Biopharma
Market Cap: US$34.0m
A biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
PPCB
US$2.49
7D
-9.5%
1Y
-96.4%
Nurix Therapeutics
Market Cap: US$725.0m
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
NRIX
US$10.14
7D
4.2%
1Y
-36.4%
Capricor Therapeutics
Market Cap: US$474.0m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$11.01
7D
50.8%
1Y
75.0%
Vanda Pharmaceuticals
Market Cap: US$254.0m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.44
7D
11.6%
1Y
-13.1%
Astria Therapeutics
Market Cap: US$240.4m
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
ATXS
US$4.29
7D
10.0%
1Y
-53.4%
Context Therapeutics
Market Cap: US$63.4m
A biopharmaceutical company, develops products for the treatment of solid tumors.
CNTX
US$0.68
7D
-17.2%
1Y
-66.6%
Ventyx Biosciences
Market Cap: US$103.2m
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
VTYX
US$1.59
7D
32.5%
1Y
-66.5%
Silence Therapeutics
Market Cap: US$234.3m
A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$5.14
7D
25.1%
1Y
-78.5%
Protara Therapeutics
Market Cap: US$131.9m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$3.48
7D
8.1%
1Y
18.8%
180 Life Sciences
Market Cap: US$6.0m
A clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States.
ATNF
US$1.15
7D
0%
1Y
-42.2%
Boundless Bio
Market Cap: US$37.8m
A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).
BOLD
US$1.66
7D
7.1%
1Y
-84.9%
Entheon Biomedical
Market Cap: CA$1.5m
Operates as a biotechnology research and development company.
ENBI
CA$0.11
7D
10.0%
1Y
-35.3%
4D Molecular Therapeutics
Market Cap: US$176.0m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$3.85
7D
17.7%
1Y
-84.7%
Monopar Therapeutics
Market Cap: US$225.6m
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
MNPR
US$36.90
7D
9.1%
1Y
1,107.7%
Sopharma AD
Market Cap: лв1.1b
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.
SFA
лв6.42
7D
0.3%
1Y
4.9%
Passage Bio
Market Cap: US$18.5m
A genetic medicines company, develops gene therapies for central nervous system diseases.
PASG
US$0.31
7D
6.5%
1Y
-75.5%
ImmunoPrecise Antibodies
Market Cap: US$22.3m
Operates as a techbio company.
IPA
US$0.49
7D
-1.4%
1Y
-56.6%
Barinthus Biotherapeutics
Market Cap: US$34.3m
A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
BRNS
US$0.89
7D
-2.2%
1Y
-58.6%
LENZ Therapeutics
Market Cap: US$800.8m
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$28.73
7D
-0.8%
1Y
54.1%
Vaxcyte
Market Cap: US$4.1b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$36.57
7D
21.7%
1Y
-50.3%
Pacira BioSciences
Market Cap: US$1.2b
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
PCRX
US$26.75
7D
14.3%
1Y
-13.4%
Onco-Innovations
Market Cap: CA$78.0m
A pre-clinical stage biotechnology company, develops drug candidates for cancer treatments.
ONCO
CA$1.45
7D
0%
1Y
n/a
Stevanato Group
Market Cap: US$6.8b
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
STVN
US$24.32
7D
-0.4%
1Y
26.3%
Synlogic
Market Cap: US$12.6m
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
SYBX
US$1.13
7D
2.7%
1Y
-31.5%
SpringWorks Therapeutics
Market Cap: US$3.5b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
SWTX
US$46.31
7D
0.2%
1Y
7.7%
Qiagen
Market Cap: US$9.3b
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
QGEN
US$42.70
7D
1.4%
1Y
-7.8%
Kyverna Therapeutics
Market Cap: US$89.5m
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
KYTX
US$2.39
7D
3.0%
1Y
-82.6%
XORTX Therapeutics
Market Cap: CA$5.5m
A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.
XRTX
CA$1.46
7D
2.1%
1Y
-58.3%
RenovoRx
Market Cap: US$45.3m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.22
7D
18.4%
1Y
-9.6%
ProKidney
Market Cap: US$236.6m
A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
PROK
US$0.79
7D
-8.6%
1Y
-78.6%
MacroGenics
Market Cap: US$100.3m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
MGNX
US$1.57
7D
1.9%
1Y
-63.1%
GH Research
Market Cap: US$725.7m
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
GHRS
US$12.45
7D
23.8%
1Y
0.7%